Apolipoprotein ciii is an important piece in the type-1 diabetes jigsaw puzzle

Ismael Valladolid-Acebes; Per Olof Berggren; Lisa Juntti-Berggren

doi:10.3390/ijms22020932

Apolipoprotein ciii is an important piece in the type-1 diabetes jigsaw puzzle

Ismael Valladolid-Acebes, Per Olof Berggren, Lisa Juntti-Berggren

Research output: Contribution to journal › Review article › peer-review

11 Citations (Scopus)

56 Downloads (Pure)

Abstract

It is well known that type-2 diabetes mellitus (T2D) is increasing worldwide, but also the autoimmune form, type-1 diabetes (T1D), is affecting more people. The latest estimation from the International Diabetes Federation (IDF) is that 1.1 million children and adolescents below 20 years of age have T1D. At present, we have no primary, secondary or tertiary prevention or treatment available, although many efforts testing different strategies have been made. This review is based on the findings that apolipoprotein CIII (apoCIII) is increased in T1D and that in vitro studies revealed that healthy β-cells exposed to apoCIII became apoptotic, together with the observation that humans with higher levels of the apolipoprotein, due to mutations in the gene, are more susceptible to developing T1D. We have summarized what is known about apoCIII in relation to inflammation and autoimmunity in in vitro and in vivo studies of T1D. The aim is to highlight the need for exploring this field as we still are only seeing the top of the iceberg.

Original language	English
Article number	932
Pages (from-to)	1-13
Number of pages	13
Journal	International Journal of Molecular Sciences
Volume	22
Issue number	2
DOIs	https://doi.org/10.3390/ijms22020932
Publication status	Published (in print/issue) - 19 Jan 2021

Bibliographical note

Funding Information:
This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Founda-tion, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860.

Funding Information:
Funding: This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Foundation, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Apolipoprotein CIII
Apoptosis
Calcium channels
Inflammation
Type-1 diabetes
β-cells
Apolipoprotein C-III/genetics
Diabetes Mellitus, Type 1/epidemiology
Humans
Insulin-Secreting Cells/metabolism
Calcium/metabolism
Diabetes Mellitus, Type 2/genetics
Inflammation/genetics
Adult
Gene Expression Regulation/genetics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms22020932Licence: CC BY

ijms-22-00932Final published version, 916 KBLicence: CC BY

Cite this

@article{82a0bd76f0e1493bbac02c8eb435d992,

title = "Apolipoprotein ciii is an important piece in the type-1 diabetes jigsaw puzzle",

abstract = "It is well known that type-2 diabetes mellitus (T2D) is increasing worldwide, but also the autoimmune form, type-1 diabetes (T1D), is affecting more people. The latest estimation from the International Diabetes Federation (IDF) is that 1.1 million children and adolescents below 20 years of age have T1D. At present, we have no primary, secondary or tertiary prevention or treatment available, although many efforts testing different strategies have been made. This review is based on the findings that apolipoprotein CIII (apoCIII) is increased in T1D and that in vitro studies revealed that healthy β-cells exposed to apoCIII became apoptotic, together with the observation that humans with higher levels of the apolipoprotein, due to mutations in the gene, are more susceptible to developing T1D. We have summarized what is known about apoCIII in relation to inflammation and autoimmunity in in vitro and in vivo studies of T1D. The aim is to highlight the need for exploring this field as we still are only seeing the top of the iceberg.",

keywords = "Apolipoprotein CIII, Apoptosis, Calcium channels, Inflammation, Type-1 diabetes, β-cells, Apolipoprotein C-III/genetics, Diabetes Mellitus, Type 1/epidemiology, Humans, Insulin-Secreting Cells/metabolism, Calcium/metabolism, Diabetes Mellitus, Type 2/genetics, Inflammation/genetics, Adult, Gene Expression Regulation/genetics",

author = "Ismael Valladolid-Acebes and Berggren, {Per Olof} and Lisa Juntti-Berggren",

note = "Funding Information: This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Founda-tion, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860. Funding Information: Funding: This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Foundation, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jan,

day = "19",

doi = "10.3390/ijms22020932",

language = "English",

volume = "22",

pages = "1--13",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI",

number = "2",

}

TY - JOUR

T1 - Apolipoprotein ciii is an important piece in the type-1 diabetes jigsaw puzzle

AU - Valladolid-Acebes, Ismael

AU - Berggren, Per Olof

AU - Juntti-Berggren, Lisa

N1 - Funding Information: This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Founda-tion, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860. Funding Information: Funding: This work was supported by Odd Fellows Grand Lodge, Sweden, the Swedish Diabetes Association, Funds of Karolinska Institutet, the Swedish Research Council, Novo Nordisk Foundation, the Family Erling-Persson Foundation, Strategic Research Program in Diabetes at Karolinska Institutet, the Stichting af Jochnick Foundation, and the ERC-EYLETS 834860. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/1/19

Y1 - 2021/1/19

N2 - It is well known that type-2 diabetes mellitus (T2D) is increasing worldwide, but also the autoimmune form, type-1 diabetes (T1D), is affecting more people. The latest estimation from the International Diabetes Federation (IDF) is that 1.1 million children and adolescents below 20 years of age have T1D. At present, we have no primary, secondary or tertiary prevention or treatment available, although many efforts testing different strategies have been made. This review is based on the findings that apolipoprotein CIII (apoCIII) is increased in T1D and that in vitro studies revealed that healthy β-cells exposed to apoCIII became apoptotic, together with the observation that humans with higher levels of the apolipoprotein, due to mutations in the gene, are more susceptible to developing T1D. We have summarized what is known about apoCIII in relation to inflammation and autoimmunity in in vitro and in vivo studies of T1D. The aim is to highlight the need for exploring this field as we still are only seeing the top of the iceberg.

AB - It is well known that type-2 diabetes mellitus (T2D) is increasing worldwide, but also the autoimmune form, type-1 diabetes (T1D), is affecting more people. The latest estimation from the International Diabetes Federation (IDF) is that 1.1 million children and adolescents below 20 years of age have T1D. At present, we have no primary, secondary or tertiary prevention or treatment available, although many efforts testing different strategies have been made. This review is based on the findings that apolipoprotein CIII (apoCIII) is increased in T1D and that in vitro studies revealed that healthy β-cells exposed to apoCIII became apoptotic, together with the observation that humans with higher levels of the apolipoprotein, due to mutations in the gene, are more susceptible to developing T1D. We have summarized what is known about apoCIII in relation to inflammation and autoimmunity in in vitro and in vivo studies of T1D. The aim is to highlight the need for exploring this field as we still are only seeing the top of the iceberg.

KW - Apolipoprotein CIII

KW - Apoptosis

KW - Calcium channels

KW - Inflammation

KW - Type-1 diabetes

KW - β-cells

KW - Apolipoprotein C-III/genetics

KW - Diabetes Mellitus, Type 1/epidemiology

KW - Humans

KW - Insulin-Secreting Cells/metabolism

KW - Calcium/metabolism

KW - Diabetes Mellitus, Type 2/genetics

KW - Inflammation/genetics

KW - Adult

KW - Gene Expression Regulation/genetics

UR - http://www.scopus.com/inward/record.url?scp=85100204201&partnerID=8YFLogxK

U2 - 10.3390/ijms22020932

DO - 10.3390/ijms22020932

M3 - Review article

C2 - 33477763

AN - SCOPUS:85100204201

SN - 1661-6596

VL - 22

SP - 1

EP - 13

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 2

M1 - 932

ER -

Apolipoprotein ciii is an important piece in the type-1 diabetes jigsaw puzzle

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this